本帖最后由 老马 于 2012-1-13 21:20 编辑
7 o, N% K A5 s! |) \+ C" S' w* K% e8 z% R
爱必妥和阿瓦斯丁的比较
' o* ?) j# g. J6 x! y4 F7 X4 f( Y. N
& \* g4 {0 H6 A6 Q! u
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/0 @& @+ h, l, n: p
8 K& I, i2 f) V: G8 o
. D- }9 ]; @" q! R, z0 ^http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* m& l& v. q+ n% a8 t. e
==================================================
3 a/ z/ F! }8 n0 N! iOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% O) U9 ]9 s% N1 QPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point., _- S: b/ i0 z
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.( x4 g. c$ [' D+ m# V- e6 ^3 p
|